Photocure ASA

Regulatory Filings • Jul 10, 2014

Photocure ASA: Expert Recommendations on the Clinical and Cost Effectiveness of Hexvix® blue-light cystoscopy published in European Urology

Photocure ASA: Expert Recommendations on the Clinical and Cost Effectiveness of Hexvix® blue-light cystoscopy published in European Urology

Oslo, Norway, 10(th) July 2014:  Photocure ASA (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, is pleased to note that updated expert recommendations on the clinical

and cost effectiveness of Hexvix have been published in European Urology.

The European expert panel, comprised of leading urologists across Europe, has

reviewed the most recent evidence on both the clinical benefits and cost

effectiveness on the use of Hexvix blue-light cystoscopy in the diagnosis and

follow up of non-muscle-invasive bladder cancer (NMIBC).

The panel concluded that Hexvix blue-light cystoscopy is a clinically effective

and cost-effective tool for improving NMIBC detection and management, thereby

reducing the burden of disease for patients and costs to the healthcare system.

The group recommends Hexvix blue-light cystoscopy for all patients with non-

muscle-invasive bladder cancer to improve initial resection and to identify

previously missed or recurrent tumors at follow-up resections, especially in

high-risk patients. Hexvix blue-light cystoscopy used at initial resection

reduces costs and improves quality-adjusted life-years compared with a resection

under white-light cystoscopy.

The European Association of Urology is one of the leading authorities in the

world on urological practice, research and education. Over 16,000 medical

professionals have joined its ranks and help to create forward-looking solutions

for continuous improvement, professional growth and knowledge sharing. The

world's leading experts contribute to the contents of the association's official

journal, European Urology, whose readership is worldwide.

Professor J A Witjes, chair of the panel, said, "We hope that our

recommendations will lead to improved care and better outcomes for patients,

through more complete resection of tumours and improved follow up. The European

expert panel's recommendations are available to support urologists in the

clinical practice of Hexvix® blue light cystoscopy in the diagnosis and follow

up of bladder cancer patients."

Kjetil Hestdal, President and CEO of Photocure, said, "Bladder cancer affects

approximately 500,000 people in Europe[1] alone and has a high recurrence rate,

up to 61% in one year and 78% over five years, making the lifetime costs of

managing bladder cancer one of the highest of all cancers. We very much welcome

the conclusions of the expert panel; they further reinforce the benefits of

using Hexvix blue-light cystoscopy across several clinical settings and the

significance to urologists, patients and payers fighting this disease."

In the analysis, the panel members highlight that appropriate use of the

technique brings benefits to patients, and to the healthcare system. In addition

to the use of Hexvix blue- light cystoscopy for all patients at initial

resection and at follow-up, the use of Hexvix blue- light cystoscopy is also

supported in several other clinical settings.

The publication "Witjes JA, et al. Clinical and Cost Effectiveness of

Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated

Expert Recommendations. Eur Urol (2014)" can be viewed at

http://www.europeanurology.com/article/S0302-2838(14)00611-3/abstract/clinical-

and-cost-effectiveness-of-hexaminolevulinate-guided-blue-light-cystoscopy-

evidence-review-and-updated-expert-recommendations

[1] International Agency for Research on Cancer. Globocan 2012: estimated cancer

incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr.

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 50 55 000, Email: ed@photocure.no

Hume Brophy

Mary Clark, Hollie Vile, Supriya Mathur

Tel: +44 20 3440 5653, Email: photocure@humebrophy.com

Notes to editors

About Photocure ASA

Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(TM) platform, Photocure develops and

commercializes highly selective and effective solutions within disease areas

with high unmet medical need, such as bladder cancer, HPV and precancerous

cervical lesions, colorectal cancer and skin conditions. Our aim is to provide

solutions which can improve health outcomes for patients worldwide. Photocure is

listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is

available at www.photocure.com.

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

[HUG#1819512]